Data Management & Statistics Jobs in Life Sciences’ Post

It is widely recognized that randomized clinical trials (RCT) are expensive, lengthy, and burdensome on patients. According to some estimates, it takes more than a billion dollars in funding and a decade of work to bring one new medication to market. While there are exciting advances in genomics, patient-centric awareness, decentralized clinical trials, and the application of artificial intelligence (AI), there is a lack of compelling evidence to date that these trends have had a significant impact on the time and cost of the typical oncology clinical trial. Nor have these developments yet had a significant impact on making clinical oncology trials less burdensome on patients.  While the highly regulated nature of the industry is clearly one of the culprits in this respect, other factors such as the industry's reluctance to change, significant data integrity issues and a bias towards incremental improvement are equally noteworthy.

Galaxy and MEAN Stack to Create a User-Friendly Workflow for the Rational Optimization of Cancer Chemotherapy. #medicalsciences #biology #medicine #health #technology #bioinformatics https://lnkd.in/dKsDY-YN

👉🏼 Enhanced Artificial Intelligence Strategies in Renal Oncology: Iterative Optimization and Comparative Analysis of GPT 3.5 Versus 4.0 🤓 Rui Liang 👇🏻 https://lnkd.in/gnEEg6Wg 🔍 Focus on data insights: - ChatGPT 4.0 outperformed ChatGPT 3.5 with a higher accuracy rate in responses. - Iterative optimization of the GPT-3.5 Turbo model stabilized response accuracy at 93.75%. - Fine-tuning and iterative optimization corrected ChatGPT's limitations in addressing renal cell carcinoma (RCC) clinical inquiries. 💡 Main outcomes and implications: - Enhanced AI strategies in renal oncology through iterative optimization and comparative analysis. - Potential for 100% response accuracy by applying iterative training methods to AI models. - Optimization of ChatGPT's database and clinical guidance capabilities in the field of renal oncology. 📚 Field significance: - Artificial Intelligence - Renal Oncology - ChatGPT - Data Insights 🗄️: #ArtificialIntelligence #RenalOncology #ChatGPT #DataInsights

Overcoming Oncology Biostatistics Challenges: Accelerate Your Drug Development

📢Alimentiv, AcelaBio AND PharmaNest PARTNER! 🤝The trio are collaborating with the shared goal of 𝘙𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘪𝘻𝘪𝘯𝘨 Precision Medicine and AI Digital Pathology for NASH/MASH Clinical Trials. It is hoped that this partnership will establish an integrated ecosystem that combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis. 🗣“𝘉𝘺 𝘤𝘳𝘦𝘢𝘵𝘪𝘯𝘨 𝘴𝘦𝘢𝘮𝘭𝘦𝘴𝘴 𝘸𝘰𝘳𝘬𝘧𝘭𝘰𝘸𝘴 𝘪𝘯𝘵𝘦𝘨𝘳𝘢𝘵𝘪𝘯𝘨 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘴𝘢𝘮𝘱𝘭𝘦 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴, 𝘥𝘪𝘨𝘪𝘵𝘢𝘭 𝘱𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺, 𝘣𝘪𝘰𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘤𝘴, 𝘢𝘯𝘥 𝘈𝘐-𝘱𝘰𝘸𝘦𝘳𝘦𝘥 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴, 𝘸𝘦 𝘤𝘢𝘯 𝘶𝘯𝘭𝘰𝘤𝘬 𝘯𝘦𝘸 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘵𝘰 𝘪𝘥𝘦𝘯𝘵𝘪𝘧𝘺 𝘣𝘪𝘰𝘮𝘢𝘳𝘬𝘦𝘳 𝘴𝘪𝘨𝘯𝘢𝘵𝘶𝘳𝘦𝘴 𝘸𝘪𝘵𝘩𝘪𝘯 𝘵𝘩𝘦 𝘴𝘱𝘢𝘵𝘪𝘢𝘭 𝘤𝘰𝘯𝘵𝘦𝘹𝘵 𝘰𝘧 𝘵𝘩𝘦 𝘵𝘪𝘴𝘴𝘶𝘦.” Niels Vande Casteele 🔬Alimentiv, AcelaBio, and PharmaNest have joined forces to propel precision medicine and digital pathology solutions into the forefront of MASH clinical trials. Together, they're leveraging their expertise to streamline early drug development, ensuring swift and efficient delivery of safe, effective treatments to patients. I for one am excited to see the inevitable positive impact to come! Read the full press release here 🔽🔽🔽 #pharmaceuticals #biotechnology #cro #precisionmedicine

🔬 **Exciting Partnership Alert!** 🔬 Alimentiv, AcelaBio, and PharmaNest are embarking on an extraordinary journey to revolutionize MASH (metabolic dysfunction-associated steatohepatitis) clinical trials through precision medicine and AI digital pathology solutions. This strategic alliance marks a significant leap forward in our collective efforts to address the complexities of metabolic liver diseases, particularly MASH, previously known as NASH. By integrating state-of-the-art spatial transcriptomics and AI-powered single-fiber and single-cell digital pathology, this collaboration empowers clinical trial sponsors to delve deeper into the histological effects and underlying mechanisms of MASH-targeted therapies. The seamless fusion of specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis creates an integrated ecosystem poised to drive scientific breakthroughs and accelerate drug development in MASH. **#PrecisionMedicine #DigitalPathology #AI #ClinicalTrials #MASH #NASH #DrugDevelopment #HealthcareInnovation #MedicalResearch #Bioinformatics #ArtificialIntelligence #PathologyInsights #Biomarkers** Niels Vande Casteele, Ph.D., President of AcelaBio, expressed, "Our collaboration holds great potential for advancing MASH clinical research, unlocking new opportunities to identify biomarker signatures within the tissue's spatial context." Wendy Teft, Ph.D., VP of Precision Medicine at Alimentiv, stated, "Through the integration of our technologies and expertise, we aim to empower clinical trial sponsors to enhance histological endpoints, uncover novel biomarkers, and expedite drug development timelines." Mathieu Petitjean, Ph.D., CEO of PharmaNest, added, "Our partnership ensures sponsors receive a superb end-to-end digital pathology tissue assay, bolstering early drug development efficiency." Synergy Healthcare applauds this alliance and eagerly anticipates opportunities to contribute to MASH research alongside these esteemed partners. Together, we're committed to advancing patient outcomes and driving innovation in the development of personalized therapies for MASH. **#Collaboration #HealthTech #ClinicalInnovation #MedicalScience #ResearchPartnership #HealthTech #DrugDiscovery #InnovativeSolutions #HealthcareCollaboration #PatientCare #MedicalBreakthroughs** 🔗 https://lnkd.in/dbjWCaBV

This. Is. Big. AI on genomics data across entire EMR systems, across all genomics vendors and their many reports in different formats and often limited accessibility, in real time. #oncologyresearch #precisionmedicine #patientmatching #clinicaltrials #genomics #rarediseaseresearch